CG Results Healthcare has advised SERB Specialty Pharmaceuticals on its acquisition of Veriton Pharma

  • Service: M&A
  • Sector: Healthcare
  • Sub Sector: Pharma & Biotech
  • Engagement Type: Buy Side
May 2020
has acquired

CG Results Healthcare is pleased to announce that it advised SERB Specialty Pharmaceuticals on its acquisition of Veriton Pharma.

This transaction highlights our exceptional track record in advising fast-growth private equity-backed businesses in the pharmaceutical sector.

SERB is a leading European specialty pharmaceutical group focused on prescription medicines that address rare and lifethreatening diseases and is backed by Charterhouse Capital Partners, one of the longest established private equity firms operating in Europe.

Founded in 1997, Veriton is a private pharmaceutical company specialising in the development of licensed and unlicensed medicines for patients with special requirements, with offices in the UK, Middle East and Australia.

The acquisition of Veriton takes the total number of add-on acquisitions made by SERB to five since November 2017, bringing SERB’s total products to around 80. During this period, SERB has transformed into a true pan-European player with direct presence in nine European countries, which will now be complemented by Veriton’s presence across the Middle East and Australia. SERB has made 50 new hires over the last two years and, following the integration Veriton, the Company’s team will be 110 strong.

CG Results was very supportive throughout the process with its strong sectorial expertise.

Arthur Pignot

M&A and Business Development VP at SERB Specialty Pharmaceuticals

Sector Related Deals

May 2022
A subsidiary of Servier
has divested its anti-LAG-3 monoclonal antibody to
A subsidiary of Sino Biopharmaceutical Limited
Mar 2022
has divested its Ringaskiddy, Ireland, manufacturing facility
Mar 2022
has divested its Boucherville, Canada manufacturing facility
Jan 2022
has divested its API manufacturing site in Cramlington, UK, to
Nov 2021
has invested in
company name confidential
Jun 2021
has acquired a drug product manufacturing facility from
May 2021
has formed a strategic alliance with
Mar 2021
has licensed the patents and know-how to its Crystalomics Formulation Technology to
Jan 2021
has divested its Mirabel manufacturing site in Riom, France to